Crispact® Finalist at CPHI Pharma Awards After Triumph at NIAwards

Crispact®, a precision probiotic containing Lactobacillus crispatus M247, has been selected as a finalist for the CPHI Pharma Awards for the third time, following its recent success at the NutraIngredients Awards. This continued recognition highlights the strength of the research behind Crispact®, including a recent pivotal study on its role in assisted reproductive technology (ART), which has significantly enhanced the understanding of its applications in fertility treatments. Despite its wide-ranging evidence in other fields, this ART study marks a crucial development for the product.

Crispact® candidate at CPHI as best finished formulation for the third time

PharmExtracta is proud to announce that Crispact®, its leading probiotic for women’s health, has been named a finalist for the CPHI Pharma Awards 2024 in the “Finished Formulation” category. This marks the third time Crispact® has earned a finalist position, following its recent win at the NutraIngredients Awards 2024 for Best Product of the Year in Microbiome Modulation.

Crispact®, based on the exclusive strain Lactobacillus crispatus M247, continues to demonstrate its impact in women’s health, particularly due to the cutting-edge research supporting its formulation. While it has shown proven efficacy in various health areas, first and foremost HPV clearance, a recent study has brought significant attention to its potential in enhancing outcomes in Assisted Reproductive Technology (ART).

The study, “Effect of L. crispatus M247 administration on pregnancy outcomes in women undergoing IVF”, involved 160 women undergoing ART procedures, with one group receiving Crispact® alongside standard hormonal therapy. The results were noteworthy, showing a 36% increase in the number of clinical pregnancies and a 67% improvement in live birth rates compared to the control group.

These outcomes mark an important development in the field of fertility treatment, positioning Crispact® as a key probiotic tool in the evolving landscape of ART. While the product’s benefits in vaginal health and the prevention of recurrent infections are well-established, this study provides a critical update on its broader applications, highlighting the growing role of precision probiotics in reproductive medicine.

As Crispact® continues to receive recognition on prestigious platforms like the CPHI Pharma Awards, PharmExtracta remains committed to advancing innovative solutions for women’s health, driven by solid scientific evidence. We look forward to showcasing Crispact® at the CPHI Awards & Networking Party 2024, on the evening of October 8th, to celebrate this achievement alongside the industry’s best.

Join Us at CPHI Milan – Stand 10F27

We invite you to join us at CPHI Milan to discover some more about Crispact® and all our extensive portfolio of probiotic and botanical supplements, as well as our medical devices and pharmaceutical products. You will find the PharmExtracta team waiting for you at the booth 10F27.

Mark your calendars and don’t miss this opportunity!